Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer DOI Open Access
Mengxing You, Jiayu Liu, Fei Teng

и другие.

Translational Lung Cancer Research, Год журнала: 2023, Номер 0(0), С. 0 - 0

Опубликована: Янв. 1, 2023

Compared with chemotherapy alone, the addition of atezolizumab to first-line treatment extensive-stage small cell lung cancer (ES-SCLC) improves overall survival (OS), but benefit remains limited. This study aims at investigating factors influencing prognosis and assess effect number induction cycles on efficacy. We retrospectively analyzed data patients ES-SCLC treated in five centers between March 2020 September 2022. All 45 received etoposide plus platinum combined atezolizumab. The primary endpoints were progression-free (PFS) OS total population subpopulations based cycles. Least absolute shrinkage selection operator (LASSO) regression applied identify prognostic variables, varying efficacy was evaluated. A enrolled study. median PFS for 7 months, 17.6 months. following 10 variables using LASSO regression: gender, age, liver metastasis, bone brain cycles, immunotherapy maintenance, receipt cross-line immunotherapy, chest radiotherapy, radiotherapy. analysis revealed that receiving ≥6 most important variable affecting only one significant [concordance index: 0.658; hazard ratio: 0.32 (95% confidence interval: 0.17-0.63)]. Patients who (n=25) had a longer (8 vs. 5 months) (18.5 13.1 than those <6 (n=20). Subgroup analyses indicated consistent benefits across key subgroups, including males, aged ≤65 years, or without metastasis (all P value <0.05). Receiving significantly prolonged patients, highlighting its crucial factor ES-SCLC.

Язык: Английский

Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer DOI Open Access
Mengxing You, Jiayu Liu, Fei Teng

и другие.

Translational Lung Cancer Research, Год журнала: 2023, Номер 0(0), С. 0 - 0

Опубликована: Янв. 1, 2023

Compared with chemotherapy alone, the addition of atezolizumab to first-line treatment extensive-stage small cell lung cancer (ES-SCLC) improves overall survival (OS), but benefit remains limited. This study aims at investigating factors influencing prognosis and assess effect number induction cycles on efficacy. We retrospectively analyzed data patients ES-SCLC treated in five centers between March 2020 September 2022. All 45 received etoposide plus platinum combined atezolizumab. The primary endpoints were progression-free (PFS) OS total population subpopulations based cycles. Least absolute shrinkage selection operator (LASSO) regression applied identify prognostic variables, varying efficacy was evaluated. A enrolled study. median PFS for 7 months, 17.6 months. following 10 variables using LASSO regression: gender, age, liver metastasis, bone brain cycles, immunotherapy maintenance, receipt cross-line immunotherapy, chest radiotherapy, radiotherapy. analysis revealed that receiving ≥6 most important variable affecting only one significant [concordance index: 0.658; hazard ratio: 0.32 (95% confidence interval: 0.17-0.63)]. Patients who (n=25) had a longer (8 vs. 5 months) (18.5 13.1 than those <6 (n=20). Subgroup analyses indicated consistent benefits across key subgroups, including males, aged ≤65 years, or without metastasis (all P value <0.05). Receiving significantly prolonged patients, highlighting its crucial factor ES-SCLC.

Язык: Английский

Процитировано

0